Clinical Trials Archives - Pharma Globenewswire

Alcohol Use Disorder Pipeline Set for Transformational Progress by 2026 with 25+ Therapies

Alcohol Use Disorder (AUD) companies such as Adial Pharmaceuticals, Imbrium Therapeutics, BioCorRx Pharmaceuticals, Beckley Psytech, Cybin, BioXcel Therapeutics, MediciNova, and others are actively redefining the future of addiction therapeutics through innovative drug development strategies, precision medicine approaches, and expanding clinical pipelines. DelveInsight’s,

21 May 2026

Clinical Trials·News·Reports

Atopic Dermatitis Pipeline Set for Transformational Expansion by 2026 with 120+ Therapies

Atopic Dermatitis companies such as Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, BioCryst Pharmaceuticals, Vanda Pharmaceuticals, and several others are actively reshaping the future of Atopic Dermatitis (AD) therapeutics through innovative drug development strategies, targeted immunological approaches, and a rapidly expanding

21 May 2026

Clinical Trials·Market Insights·News·Reports

Niemann-Pick Disease Market Forecast 2034 | Medication, Statistics, Revenue, Treatment, Therapies and Companies

According to DelveInsight’s analysis, the market for Niemann-Pick disease is anticipated to increase during the forecast period (2025–2034), owing to the rise in the launch of emerging therapies and healthcare spending globally. DelveInsight has recently released epidemiology-based market reports focusing on Niemann-Pick

13 May 2026

Clinical Trials·Drug Launches & Approvals·News·Reports

PROTAC Market Forecast Signals Robust Growth Through 2034

The PROTAC market is witnessing substantial momentum owing to the growing demand for next-generation targeted therapeutics capable of degrading disease-causing proteins previously considered “undruggable.” Rising investments in oncology research, rapid advances in targeted protein degradation (TPD) technologies, and increasing clinical success of

7 May 2026

Clinical Trials·Drug Launches & Approvals·News·Reports

Orforglipron Market Set for Significant Expansion Through 2034

The global metabolic disease treatment landscape is rapidly evolving, and one investigational therapy attracting substantial industry attention is orforglipron, Eli Lilly and Company’s once-daily oral GLP-1 receptor agonist. With strong late-stage clinical data, expanding therapeutic applications, and increasing demand for convenient obesity

7 May 2026

Clinical Trials·News·Reports

Thyroid Eye Disease Pipeline Accelerates with 20+ Companies Advancing Innovative Therapies Across Clinical Stages

Thyroid Eye Disease (TED), also known as Graves’ ophthalmopathy, is a serious autoimmune inflammatory condition that targets the orbital tissues, including muscles and fat surrounding the eyes. Closely linked to Graves’ disease and other thyroid dysfunctions, TED often emerges in patients with

23 April 2026

Clinical Trials·News·Reports

Celiac Disease Pipeline Advances as 25+ Companies Progress 30+ Therapies Across Clinical Trials

Key companies actively involved in the celiac disease drug development landscape include Takeda, Anokion SA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX Inc., Amgen Inc., and several other emerging biotechnology innovators. According to DelveInsight’s latest

21 April 2026

Clinical Trials·News·Reports

Melanoma Clinical Trials 2025: EMA, PDMA, FDA Approvals and Companies

Melanoma Companies are IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others. (Albany, USA) DelveInsight’s, “Melanoma Pipeline

20 April 2026

Clinical Trials·Reports

Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

DelveInsight’s “Lassa Fever – Pipeline Insight, 2026” provides a detailed view of the evolving pipeline, emphasizing efforts to deliver first-in-class therapies and vaccines to endemic populations. The report highlights global R&D activity, platform technologies, and regulatory incentives accelerating development timelines.Lassa Fever, an

9 April 2026

Clinical Trials·Reports

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise in aging populations is significantly increasing the at-risk patient base.

9 April 2026

Clinical Trials

GSK’s Bepirovirsen Demonstrates Statistically Significant Functional Cure Rates in Chronic Hepatitis B

Alcohol Use Disorder Pipeline Set for Transformational Progress by 2026 with 25+ Therapies

Atopic Dermatitis Pipeline Set for Transformational Expansion by 2026 with 120+ Therapies

Niemann-Pick Disease Market Forecast 2034 | Medication, Statistics, Revenue, Treatment, Therapies and Companies

PROTAC Market Forecast Signals Robust Growth Through 2034

Orforglipron Market Set for Significant Expansion Through 2034

Thyroid Eye Disease Pipeline Accelerates with 20+ Companies Advancing Innovative Therapies Across Clinical Stages

Celiac Disease Pipeline Advances as 25+ Companies Progress 30+ Therapies Across Clinical Trials

Melanoma Clinical Trials 2025: EMA, PDMA, FDA Approvals and Companies

Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain

Recent Posts

Banner

Newsletter

Authors

pharmaglobenews

Michael Ashford

FDA Approves Otsuka’s VOYXACT (Sibeprenlimab-szsi): A Breakthrough in Primary Immunoglobulin A Nephropathy Treatment

Suggestions

Clinical Trials

Recent Posts

Banner

Newsletter

Authors